Clearmind Medicine Starts US Trial for Alcohol Use Disorder
Ticker: CMND · Form: 6-K · Filed: Apr 10, 2025 · CIK: 1892500
| Field | Detail |
|---|---|
| Company | Clearmind Medicine INC. (CMND) |
| Form Type | 6-K |
| Filed Date | Apr 10, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, drug-development, healthcare
TL;DR
Clearmind starts US trial for CMND-100 in alcohol disorder patients.
AI Summary
Clearmind Medicine Inc. announced on April 10, 2025, the initiation of its first U.S. clinical site for the CMND-100 Phase 2b trial. This trial will evaluate CMND-100 for the treatment of Alcohol Use Disorder (AUD). The company is a pharmaceutical preparations company based in Vancouver, British Columbia.
Why It Matters
This marks a significant step in the development of a potential new treatment for Alcohol Use Disorder, a condition affecting millions globally.
Risk Assessment
Risk Level: medium — Clinical trial initiations are positive but carry inherent risks related to trial success, regulatory approval, and market adoption.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Filer of the 6-K report and developer of CMND-100
- CMND-100 (drug_candidate) — Investigational drug for Alcohol Use Disorder
- Alcohol Use Disorder (medical_condition) — Condition being treated by CMND-100
- April 10, 2025 (date) — Date of the press release and filing
FAQ
What is the purpose of the CMND-100 clinical trial?
The CMND-100 Phase 2b clinical trial is designed to evaluate CMND-100 for the treatment of Alcohol Use Disorder.
Where has the first U.S. clinical site for the CMND-100 trial been initiated?
The filing states that the first U.S. clinical site has been initiated, but does not specify the exact location of the site.
What is Clearmind Medicine Inc.'s primary business?
Clearmind Medicine Inc. is in the business of pharmaceutical preparations, as indicated by its SIC code 2834.
What form is Clearmind Medicine Inc. filing with the SEC?
Clearmind Medicine Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
When is Clearmind Medicine Inc.'s fiscal year end?
Clearmind Medicine Inc.'s fiscal year ends on October 31st (1031).
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 10, 2025 regarding Clearmind Medicine Inc. (CMND).